Kenneth J. Kelley, Director at HALOZYME THERAPEUTICS INC (HTI), sold 25,000 shares at $9.01 ($221K) on 2007-04-23, disclosed to the SEC on 2007-04-24.
Scheduled sale ($221k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.75 | 1,700 | $15K | 6.7% |
| 2 | $8.76 | 1,875 | $16K | 7.4% |
| 3 | $8.77 | 300 | $3K | 1.2% |
| 4 | $8.78 | 2,000 | $18K | 7.9% |
| 5 | $8.79 | 2,600 | $23K | 10.3% |
| 6 | $8.80 | 2,000 |
| $18K |
| 8.0% |
| 7 | $8.81 | 1,825 | $16K | 7.3% |
| 8 | $8.82 | 300 | $3K | 1.2% |
| 9 | $8.83 | 300 | $3K | 1.2% |
| 10 | $8.84 | 1,900 | $17K | 7.6% |
| 11 | $8.85 | 2,500 | $22K | 10.0% |
| 12 | $8.86 | 1,400 | $12K | 5.6% |
| 13 | $8.87 | 600 | $5K | 2.4% |
| 14 | $8.88 | 500 | $4K | 2.0% |
| 15 | $8.90 | 300 | $3K | 1.2% |
| 16 | $8.91 | 400 | $4K | 1.6% |
| 17 | $8.92 | 400 | $4K | 1.6% |
| 18 | $8.93 | 300 | $3K | 1.2% |
| 19 | $8.94 | 200 | $2K | 0.8% |
| 20 | $8.95 | 1,500 | $13K | 6.1% |
| 21 | $8.96 | 300 | $3K | 1.2% |
| 22 | $8.98 | 200 | $2K | 0.8% |
| 23 | $9.00 | 200 | $2K | 0.8% |
| 24 | $9.01 | 800 | $7K | 3.3% |
| 25 | $9.03 | 100 | $903 | 0.4% |
| 26 | $9.05 | 400 | $4K | 1.6% |
| 27 | $9.10 | 100 | $910 | 0.4% |
| Total | $8.84 avg | 25,000 | $221K | 100% |
| Filing → |
| HALO | SELL | 2021-02-01 | $469K | — | Filing → |
| HALO | SELL | 2021-01-04 | $417K | — | Filing → |
| HALO | SELL | 2020-12-07 | $1.4M | — | Filing → |